{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T00:21:26Z","timestamp":1793578886055,"version":"4.5.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"DOI":"10.1186\/s10194-025-02138-5","type":"journal-article","created":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T13:27:55Z","timestamp":1756733275000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["A nomogram for the prediction of response to anti-CGRP mAbs: the CGRP score"],"prefix":"10.1186","volume":"26","author":[{"given":"Marina","family":"Romozzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ammar","family":"Lokhandwala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catello","family":"Vollono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Garc\u00eda-Azor\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Vigani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"De Cesaris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Altamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Vernieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Calabresi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Di Tella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi Francesco","family":"Iannone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,1]]},"reference":[{"issue":"10483","key":"2138_CR1","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/S0140-6736(25)00109-6","volume":"405","author":"J Versijpt","year":"2025","unstructured":"Versijpt J, Paemeleire K, Reuter U, MaassenVanDenBrink A (2025) Calcitonin gene-related peptide-targeted therapy in migraine: current role and future perspectives. Lancet 405(10483):1014\u20131026","journal-title":"Lancet"},{"issue":"1","key":"2138_CR2","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s10194-022-01498-6","volume":"23","author":"P Barbanti","year":"2022","unstructured":"Barbanti P, Egeo G, Aurilia C, Altamura C, d\u2019Onofrio F, Finocchi C et al (2022) Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients. J Headache Pain 23(1):138","journal-title":"J Headache Pain"},{"issue":"6","key":"2138_CR3","doi-asserted-by":"publisher","first-page":"364","DOI":"10.3390\/toxins15060364","volume":"15","author":"D Martinelli","year":"2023","unstructured":"Martinelli D, Pocora MM, De Icco R, Allena M, Vaghi G, Sances G et al (2023) Searching for the predictors of response to BoNT-A in migraine using machine learning approaches. Toxins 15(6):364","journal-title":"Toxins"},{"issue":"10","key":"2138_CR4","doi-asserted-by":"publisher","first-page":"3102","DOI":"10.1111\/ene.15458","volume":"29","author":"A Gonzalez-Martinez","year":"2022","unstructured":"Gonzalez-Martinez A, Pag\u00e1n J, Sanz-Garc\u00eda A, Garc\u00eda-Azor\u00edn D, Rodr\u00edguez-Vico JS, Jaimes A et al (2022) Machine-learning-based approach for predicting response to anti-calcitonin gene-related peptide (CGRP) receptor or ligand antibody treatment in patients with migraine: A multicenter Spanish study. Eur J Neurol 29(10):3102\u20133111","journal-title":"Eur J Neurol"},{"issue":"12","key":"2138_CR5","doi-asserted-by":"publisher","first-page":"033310242412627","DOI":"10.1177\/03331024241262751","volume":"44","author":"M Romozzi","year":"2024","unstructured":"Romozzi M, Lokhandwala A, Vollono C, Vigani G, Burgalassi A, Garc\u00eda-Azor\u00edn D et al (2024) An evolving machine-learning-based algorithm to early predict response to anti-CGRP monoclonal antibodies in patients with migraine. Cephalalgia 44(12):03331024241262751","journal-title":"Cephalalgia"},{"issue":"1","key":"2138_CR6","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1186\/s10194-024-01924-x","volume":"25","author":"I Petru\u0161i\u0107","year":"2024","unstructured":"Petru\u0161i\u0107 I, Savi\u0107 AA, Mitrovi\u0107 K, Ba\u010danin N, Sebastianelli G, Secci D et al (2024) Machine learning classification Meets migraine: recommendations for study evaluation. J Headache Pain 25(1):215","journal-title":"J Headache Pain"},{"key":"2138_CR7","doi-asserted-by":"crossref","unstructured":"Headache Classification Committee of the International Headache Society (IHS) (2018) The international classification of headache disorders, 3rd edition. Cephalalgia 38(1):1\u2013211","DOI":"10.1177\/0333102417738202"},{"issue":"5","key":"2138_CR8","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1177\/0333102418758283","volume":"38","author":"C Tassorelli","year":"2018","unstructured":"Tassorelli C, Diener HC, Dodick DW, Silberstein SD, Lipton RB, Ashina M et al (2018) Guidelines of the international headache society for controlled trials of preventive treatment of chronic migraine in adults. Cephalalgia 38(5):815\u2013832","journal-title":"Cephalalgia"},{"key":"2138_CR9","doi-asserted-by":"publisher","first-page":"e12743","DOI":"10.7717\/peerj.12743","volume":"10","author":"F Liu","year":"2022","unstructured":"Liu F, Bao G, Yan M, Lin G (2022) A decision support system for primary headache developed through machine learning. PeerJ 10:e12743","journal-title":"PeerJ"},{"issue":"1","key":"2138_CR10","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12911-017-0434-4","volume":"17","author":"Y Garcia-Chimeno","year":"2017","unstructured":"Garcia-Chimeno Y, Garcia-Zapirain B, Gomez-Beldarrain M, Fernandez-Ruanova B, Garcia-Monco JC (2017) Automatic migraine classification via feature selection committee and machine learning techniques over imaging and questionnaire data. BMC Med Inf Decis Mak 17(1):38","journal-title":"BMC Med Inf Decis Mak"},{"key":"2138_CR11","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1016\/j.csbj.2020.06.006","volume":"18","author":"P Ferroni","year":"2020","unstructured":"Ferroni P, Zanzotto FM, Scarpato N, Spila A, Fofi L, Egeo G et al (2020) Machine learning approach to predict medication overuse in migraine patients. Comput Struct Biotechnol J 18:1487\u20131496","journal-title":"Comput Struct Biotechnol J"},{"issue":"9","key":"2138_CR12","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1111\/head.14806","volume":"64","author":"CC Chiang","year":"2024","unstructured":"Chiang CC, Schwedt TJ, Dumkrieger G, Wang L, Chao CJ, Ouellette HA et al (2024) Advancing toward precision migraine treatment: predicting responses to preventive medications with machine learning models based on patient and migraine features. Headache 64(9):1094\u20131108","journal-title":"Headache"},{"issue":"2","key":"2138_CR13","first-page":"e54030","volume":"16","author":"V Reddy","year":"2024","unstructured":"Reddy V, Reddy H, Gemnani R, Kumar S, Acharya S (2024) Navigating the complexity of scoring systems in sepsis management: A comprehensive review. Cureus 16(2):e54030","journal-title":"Cureus"},{"issue":"1","key":"2138_CR14","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s10194-022-01480-2","volume":"23","author":"R De Icco","year":"2022","unstructured":"De Icco R, Vaghi G, Allena M, Ghiotto N, Guaschino E, Martinelli D et al (2022) Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial. J Headache Pain 23(1):123","journal-title":"J Headache Pain"},{"issue":"2","key":"2138_CR15","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s40263-021-00893-y","volume":"36","author":"LF Iannone","year":"2022","unstructured":"Iannone LF, Fattori D, Benemei S, Chiarugi A, Geppetti P, De Cesaris F (2022) Long-Term effectiveness of three Anti-CGRP monoclonal antibodies in resistant chronic migraine patients based on the MIDAS score. CNS Drugs 36(2):191\u2013202","journal-title":"CNS Drugs"},{"issue":"11","key":"2138_CR16","doi-asserted-by":"publisher","first-page":"333102424127396","DOI":"10.1177\/03331024241273968","volume":"44","author":"A Burgalassi","year":"2024","unstructured":"Burgalassi A, Romozzi M, Vigani G, De Icco R, Raffaelli B, Boccalini A et al (2024) Outcomes, unmet needs, and challenges in the management of patients who withdraw from anti-CGRP monoclonal antibodies: A prospective cohort study. Cephalalgia 44(11):3331024241273968","journal-title":"Cephalalgia"},{"issue":"6","key":"2138_CR17","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1002\/acn3.70053","volume":"12","author":"M Romozzi","year":"2025","unstructured":"Romozzi M, Vollono C, Calabresi P, De Cesaris F, Iannone LF (2025) Patients\u2019 global impression of change (PGIC) score compared to monthly migraine days to evaluate treatment persistence with Anti-CGRP monoclonal antibodies. Ann Clin Transl Neurol 12(6):1292\u20131295","journal-title":"Ann Clin Transl Neurol"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-025-02138-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-025-02138-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-025-02138-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T10:04:11Z","timestamp":1773828251000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s10194-025-02138-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2138"],"URL":"https:\/\/doi.org\/10.1186\/s10194-025-02138-5","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,1]]},"assertion":[{"value":"17 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"LFI received fees and Honoraria for advisory boards and speaker panels from Teva, Eli Lilly, Lundbeck, Pfizer, Organon and AbbVie. CV received fees, Honoraria for advisory boards, support for attending meetings and\/or travel and speaker panels from Teva, Eli Lilly, Lundbeck, Pfizer, and AbbVie. MR received support for attending meetings and\/or travel from AbbVie and Lundbeck. PC received fees, Honoraria for advisory boards, support for attending meetings and\/or travel and speaker panels from AbbVie, Bayer Schering, Bial, Biogen-Domp\u00e8, Biogen-Idec, Eisai, Genzyme, Lundbeck, Lusofarmaco, Merck-Serono, Novartis, Prexton, Teva, UCB Pharma, and Zambon. Other authors have no conflicting interests relevant to the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"190"}}